Data | Hora | Fonte | Título | Código | Companhia |
27/02/2008 | 09:30 | Business Wire | Allos Therapeutics Reports 2007 Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
21/02/2008 | 19:55 | Edgar (US Regulatory) | Allos Therapeutics Inc - Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
14/02/2008 | 18:52 | Edgar (US Regulatory) | Allos Therapeutics Inc - Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
14/02/2008 | 13:54 | Edgar (US Regulatory) | Allos Therapeutics Inc - Statement of Ownership (SC 13G) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
11/02/2008 | 11:00 | Business Wire | Allos Therapeutics to Report 2007 Results on February 27, 2008 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
04/02/2008 | 18:23 | Edgar (US Regulatory) | Allos Therapeutics Inc - Initial Statement of Beneficial Ownership (3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
29/01/2008 | 11:00 | PR Newswire (US) | Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
28/01/2008 | 11:00 | PR Newswire (US) | Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/01/2008 | 19:47 | Edgar (US Regulatory) | Allos Therapeutics Inc - Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/01/2008 | 11:00 | PR Newswire (US) | Allos Therapeutics Initiates Phase 2b Study of PDX in Patients With Non-small Cell Lung Cancer | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
27/12/2007 | 11:00 | PR Newswire (US) | Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Periph | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
11/12/2007 | 11:00 | PR Newswire (US) | Allos Therapeutics to Present at the 2008 JPMorgan Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/12/2007 | 11:00 | PR Newswire (US) | Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
29/11/2007 | 11:00 | PR Newswire (US) | Allos Therapeutics to Present at the 2007 BMO Capital Markets Focus on Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
20/11/2007 | 11:00 | PR Newswire (US) | Allos Therapeutics to Present at the 2007 Lazard Capital Markets Healthcare Investor Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
12/11/2007 | 19:00 | PR Newswire (US) | Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/11/2007 | 19:00 | PR Newswire (US) | Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/11/2007 | 17:02 | Edgar (US Regulatory) | Allos Therapeutics Inc - Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/11/2007 | 10:30 | PR Newswire (US) | Allos Therapeutics Reports Third Quarter 2007 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
31/10/2007 | 10:00 | PR Newswire (US) | Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
25/10/2007 | 18:01 | PR Newswire (US) | Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
16/10/2007 | 09:55 | PR Newswire (US) | Allos Therapeutics to Report 2007 Third Quarter Financial Results on November 5, 2007 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
26/09/2007 | 11:43 | Edgar (US Regulatory) | Allos Therapeutics Inc (Other) (SC 13G) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
24/09/2007 | 16:35 | Edgar (US Regulatory) | Allos Therapeutics Inc (Other) (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
24/09/2007 | 08:30 | PR Newswire (US) | Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
13/09/2007 | 09:00 | PR Newswire (US) | Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
04/09/2007 | 09:00 | PR Newswire (US) | Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
15/08/2007 | 09:00 | PR Newswire (US) | Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/08/2007 | 10:00 | PR Newswire (US) | Allos Therapeutics Reports Second Quarter 2007 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
18/07/2007 | 09:00 | PR Newswire (US) | Allos Therapeutics to Report 2007 Second Quarter Financial Results on August 7, 2007 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |